Corvus Pharmaceuticals remains firmly in clinical-stage development with no commercial products as of 2025, focusing on immune-targeted therapies through internal R&D and external licensing arrangements. Despite a near 56% increase in operating losses year-over-year, the company has strengthened its liquidity position, maintaining a current ratio above six through significant cash and marketable securities. Critical upcoming milestones include continued clinical trial progress for key candidates like ciforadenant and mupadolimab, while the strategic amended sales agreement with Jefferies boosts capital raising flexibility amid competitive market pressures.